Top Stories Thursday, November 17, 2016 A new “boutique biotech hotel” building project is today in front of officials as they decide on the future development of a potential new life sciences community in South San Francisco. Thursday, November 17, 2016 J&J’s biotech arm has submitted its application to the FDA for its experimental med guselkumab in moderate to severe plaque psoriasis. Thursday, November 17, 2016 New York-based biotech Syntimmune has gained biopharma and VC veteran David de Graaf as its new president and CEO as the company gains the final $8 million from its Series A. Thursday, November 17, 2016 Grünenthal has bought Thar Pharmaceuticals to add another complex regional pain syndrome candidate to its late-phase pipeline. The takeover means Grünenthal now owns two of the leading pipeline prospects in CRPS, a recently-minted orphan disease for which no drugs are approved in the U.S. or Europe. Thursday, November 17, 2016 Amgen has chalked up another positive trial for its new migraine candidate erenumab as it vies to beat rivals Teva, Eli Lilly and Alder Biopharmaceuticals to market. Wednesday, November 16, 2016 The European Medicines Agency has followed through on plans to update its guidance on first-in-human clinical trials in light of a fatality in a French study earlier this year. Wednesday, November 16, 2016 When drug-price critic Hillary Clinton unexpectedly lost the election last week, it was little surprise that shares of drug companies rallied, with the Nasdaq Biotech Index jumping 9% the day after the election—its biggest one-day spike in eight years. But is Wall Street's optimism premature? | | | The FDA has handed out its fast track tag for Biogen and Eisai's BACE inhibitor in early Alzheimer's. Release ProMetic says its experimental med PBI-4050 has shown some early signals of efficacy in a midstage study for the lung-scarring disease IPF. Statement Roche comes under more pressure as Boehringer says its bevacizumab biosimilar candidate shows bioequivalence to its cancer blockbuster Avastin in a new test. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Immunotherapy: Mapping the Future of Cancer Drug Discovery November 28, 2016 | Munich, Germany 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA | 